APC resistance in patients with and without vessel disease;APC-Resistenz bei Patienten mit und ohne Gefasserkrankungen

Phlebologie

Volumn 27, Issue 1, 1998, Pages 19-24

  Runge, Eva ^a   Siegert, G ^b   Gehrisch, S ^b   Schroder H E ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Inst F Klin Chem L

Author keywords

APC resistance; Family study; Vessel disease

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; VASCULAR DISEASE; VEIN THROMBOSIS;

EID: 0031868336     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617215     Document Type: Article

References (17)

1. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsman PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
2. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
3. Cadroy Y, Sié P, Alhenc-Gelas M, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Letters to the Editor. Thromb Haemost 1995; 73: 727-38.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci, USA 1993; 90: 1004-8.
5. 506 to Gln Mutation in the factor V gene, and venous thrombosis. Thromb Haemost 1995; 73: 739-42.
6. 506 to Gln mutation in factor V as a pathogenic factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
7. Gehrisch S, Jaroß W. Diagnostische Festphasensequenzierung PCR-amplifizierter genomischer DNA-Poolsequenzierung. Klin Lab 1993; 39: 887-94.
8. Griffin JH, Heeb MJ, Kojima Y, Fenandez JA, Kojima K, Hackeng TM, Greengard JS. Activated protein C resistance: Molecular mechanisms. Thromb Haemost 1995; 74: 444-8.
9. 506 factor V. Blood 1995; 85: 3405-11.
10. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. The Lancet 1994; 344: 1162-3.
11. Kalafatis M, Rand MR, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 50: 31869-80.
12. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated Protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
13. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
14. Siegert G, Gehrisch S, Runge E, Schwarz Th, Schimmanck S, Schellong S, Lüthke K, Naumann R, Knöfler R. Vergleich der Response gegenüber aktiviertem Protein C in unterschiedlichen Testsystemen mit dem Ergebnis der Faktor V Genotypisierung (Arg 506 → Gln). Hämostaseologie 1997; 17: 170-5.
15. Trosseaërt M, Conrad J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. The Lancet 1994; 344: 1709.
16. Varadi K, Moritz B, Lang H, Bauer K, Preston E, Paeke I, Rivard GE, Keil B, Schwarz HP. A chromogenic assay for activated protein C resistance. British J Haematol 1995; 90: 884-91.
17. Zöller B, Berntsdotter A, de Fructos PC, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.